Drug Use Investigation of Riociguat for Pulmonary Arterial Hypertension (PAH)

Trial Profile

Drug Use Investigation of Riociguat for Pulmonary Arterial Hypertension (PAH)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms JPMS-PAH
  • Sponsors Bayer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Jul 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
    • 15 Jun 2015 Planned initiation date changed from 1 May 2015 to 1 Jun 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top